A Phase 2 Multicenter Study of the Combination Zanubrutinib, Bendamustine, and Rituximab in Previously Untreated Waldenström Macroglobulinemia (ZEBRA Trial)

This study is testing a new combination of three different medications to treat a rare blood cancer called Waldenström macroglobulinemia. Researchers want to see if using these drugs together can help patients achieve a strong, positive response and better control their cancer.

This study is for people who have been newly diagnosed with Waldenström macroglobulinemia and are experiencing symptoms like fevers, night sweats, or weight loss. You must have your genetic mutation status tested to join, and you cannot participate if you have certain other infections or if the cancer has spread to your brain.

Participants will receive a combination of three treatments: zanubrutinib (which blocks cancer growth signals), bendamustine (a chemotherapy to damage cancer cells), and rituximab (an antibody that helps your immune system fight the cancer). You will be monitored closely by a medical team throughout the process to ensure your safety.

The study is currently recruiting new participants at medical centers in Denver, Colorado, and Boston, Massachusetts. Please speak with your doctor to see if one of these locations is an option for you.